Cristina Müller (CRS) receives the Marie Curie Award
The Marie Curie Award, the most prestigious price by the European Association of Nuclear Medicine, has been awarded in 2018 for the project "Terbium-161 for PSMA-Targeted Radionuclide Therapy of Prostate Cancer", lead by Christina Müller in collaboration with Nick van der Meulen (LRC/NES) EANM-Website(link is external). The team lead by Cristina Müller demonstrated that 161Terbium is a potentially highly effective therapeutic alternative to 177Lu-PSMA-617. Prostate-specific membrane antigen (PSMA), a membrane zinc metalloenzyme, emerged in the last yeards as an interesting target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). PSMA-617 is a small molecule targeting PSMA with high affinity and can be labeled with various radionuclides for diagnostic and therapeutic purposes. Cristina Müller and co-workers demonstrated that 161Tb-PSMA-617 has an improved absorbed dose profile compared to 177Lu-PSMA-617.